Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Ophthalmology
Published in: BMC Ophthalmology 1/2014

Open Access 01-12-2014 | Research article

Blood expression levels of chemokine receptor CCR3 and chemokine CCL11 in age-related macular degeneration: a case–control study

Authors: Mads Krüger Falk, Amardeep Singh, Carsten Faber, Mogens Holst Nissen, Thomas Hviid, Torben Lykke Sørensen

Published in: BMC Ophthalmology | Issue 1/2014

Login to get access

Abstract

Background

Dysregulation of the CCR3/CCL11 pathway has been implicated in the pathogenesis of choroidal neovascularisation, a common feature of late age-related macular degeneration (AMD). The aim of this study was to investigate the expression of CCR3 and its ligand CCL11 in peripheral blood in patients with neovascular AMD.

Methods

Patients with neovascular AMD and healthy controls were included. Blood samples were obtained and prepared for flow cytometry to investigate the expression of CCR3. Levels of CCL11 were measured in plasma using Cytometric Bead Array. Differences between the groups were tested using Kruskal-Wallis test and Mann–Whitney U test.

Results

Patients (n = 83) with neovascular AMD and healthy control persons (n = 114) were included in the study. No significant difference in the expression of CCR3 was found on CD9+ granulocytes when comparing patients suffering from neovascular AMD with any of the control groups. We did not find any alteration in CCL11 levels in patients among the age matched groups. There was no correlation between expression of CCR3/CCL11 and clinical response to treatment with anti-vascular endothelial growth factor (VEGF).

Conclusion

Our results do not suggest a systemic alteration of the CCR3/CCL11 receptor/ligand complex in patients with neovascular AMD.
Appendix
Available only for authorised users
Literature
1.
Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY: Age-related macular degeneration. Lancet. 2012, 379 (9827): 1728-1738. 10.1016/S0140-6736(12)60282-7.CrossRefPubMed
2.
Ferris FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR, Beckman Initiative for Macular Research Classification C: Clinical classification of age-related macular degeneration. Ophthalmology. 2013, 120 (4): 844-851. 10.1016/j.ophtha.2012.10.036.CrossRefPubMed
3.
Kruger Falk M, Kemp H, Sorensen TL: Four-Year Treatment Results of Neovascular Age-Related Macular Degeneration With Ranibizumab and Causes for Discontinuation of Treatment. Am J Ophthalmol. 2012, 155 (1): 89-95.CrossRefPubMed
4.
Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J: CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature. 2009, 460 (7252): 225-230. 10.1038/nature08151.CrossRefPubMedPubMedCentral
5.
Wang H, Wittchen ES, Jiang Y, Ambati B, Grossniklaus HE, Hartnett ME: Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling. Invest Ophthalmol Visual Sci. 2011, 52 (11): 8271-8277. 10.1167/iovs.11-8230.CrossRef
6.
Xie P, Kamei M, Suzuki M, Matsumura N, Nishida K, Sakimoto S, Sakaguchi H, Nishida K: Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344. PloS One. 2011, 6 (12): e28933-10.1371/journal.pone.0028933.CrossRefPubMedPubMedCentral
7.
Eghoj MS, Sorensen TL: Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012, 96 (1): 21-23. 10.1136/bjo.2011.203893.CrossRefPubMed
8.
Salcedo R, Young HA, Ponce ML, Ward JM, Kleinman HK, Murphy WJ, Oppenheim JJ: Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol. 2001, 166 (12): 7571-7578.CrossRefPubMed
9.
Rossi D, Zlotnik A: The biology of chemokines and their receptors. Ann Rev Immunol. 2000, 18: 217-242. 10.1146/annurev.immunol.18.1.217.CrossRef
10.
Pease JE, Williams TJ: Chemokines and their receptors in allergic disease. J Allergy Clin Immunol. 2006, 118 (2): 305-318. 10.1016/j.jaci.2006.06.010. quiz 319–320CrossRefPubMed
11.
Sharma NK, Gupta A, Prabhakar S, Singh R, Bhatt AK, Anand A: CC chemokine receptor-3 as new target for age-related macular degeneration. Gene. 2013, 523 (1): 106-111. 10.1016/j.gene.2013.03.052.CrossRefPubMed
12.
Rankin SM, Conroy DM, Williams TJ: Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today. 2000, 6 (1): 20-27. 10.1016/S1357-4310(99)01635-4.CrossRefPubMed
13.
Jeon H, Mun GI, Boo YC: Analysis of serum cytokine/chemokine profiles affected by aging and exercise in mice. Cytokine. 2012, 60 (2): 487-492. 10.1016/j.cyto.2012.07.014.CrossRefPubMed
14.
Shurin GV, Yurkovetsky ZR, Chatta GS, Tourkova IL, Shurin MR, Lokshin AE: Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine. 2007, 39 (2): 123-129. 10.1016/j.cyto.2007.06.006.CrossRefPubMed
15.
Sharma NK, Prabhakar S, Gupta A, Singh R, Gupta PK, Gupta PK, Anand A: New biomarker for neovascular age-related macular degeneration: eotaxin-2. DNA Cell Biol. 2012, 31 (11): 1618-1627. 10.1089/dna.2012.1786.CrossRefPubMed
16.
Singh A, Falk MK, Hviid TV, Sorensen TL: Increased expression of CD200 on circulating CD11b + monocytes in patients with neovascular age-related macular degeneration. Ophthalmology. 2013, 120 (5): 1029-1037. 10.1016/j.ophtha.2012.11.002.CrossRefPubMed
17.
Burgisser P, Vaudaux J, Bart PA: Severe interference between retinal angiography and automated four-color flow cytometry analysis of blood mononuclear cells. Cytometry Part A: J Int Soc Anal Cytol. 2007, 71 (8): 632-636.CrossRef
18.
Bloch SB, la Cour M, Sander B, Hansen LK, Fuchs J, Lund-Andersen H, Larsen M: Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol. 2013, 91 (1): 42-47. 10.1111/j.1755-3768.2011.02268.x.CrossRefPubMed
19.
Miller JW: Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2013, 155 (1): 1-35 e13-CrossRefPubMed
20.
Romagnani P, De Paulis A, Beltrame C, Annunziato F, Dente V, Maggi E, Romagnani S, Marone G: Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am J Pathol. 1999, 155 (4): 1195-1204. 10.1016/S0002-9440(10)65222-4.CrossRefPubMedPubMedCentral
21.
Mizutani T, Ashikari M, Tokoro M, Nozaki M, Ogura Y: Suppression of Laser-Induced Choroidal Neovascularization by a CCR3 Antagonist. Invest Ophthalmol Visual Sci. 2013, 54 (2): 1564-1572. 10.1167/iovs.11-9095.CrossRef
22.
Ahmad I, Balasubramanian S, Del Debbio CB, Parameswaran S, Katz AR, Toris C, Fariss RN: Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration. Invest Ophthalmol Visual Sci. 2011, 52 (6): 2868-2878. 10.1167/iovs.10-6608.CrossRef
23.
24.
Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Despres S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T: The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011, 477 (7362): 90-94. 10.1038/nature10357.CrossRefPubMedPubMedCentral
25.
Mo FM, Proia AD, Johnson WH, Cyr D, Lashkari K: Interferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. Invest Ophthalmol Visual Sci. 2010, 51 (8): 4226-4236. 10.1167/iovs.09-3910.CrossRef
Metadata
Title
Blood expression levels of chemokine receptor CCR3 and chemokine CCL11 in age-related macular degeneration: a case–control study
Authors
Mads Krüger Falk
Amardeep Singh
Carsten Faber
Mogens Holst Nissen
Thomas Hviid
Torben Lykke Sørensen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2014
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/1471-2415-14-22

Other articles of this Issue 1/2014

BMC Ophthalmology 1/2014 Go to the issue

Case report

Detection of underdiagnosed concurrent branch retinal artery occlusion in a patient with central retinal vein occlusion using spectral domain optical coherence tomography

Reviewer acknowledgement

Reviewer acknowledgement 2013

Research article

Analysis of neuroretinal rim distribution and vascular pattern in eyes with presumed large physiological cupping: a comparative study

Research article

Low vision due to cerebral visual impairment: differentiating between acquired and genetic causes

Case report

Deferoxamine retinopathy: spectral domain-optical coherence tomography findings

Case report

Spontaneous closure of a myopic macular hole with retinal reattachment in an eye with high myopia and staphyloma: a case report